IPO round-up: K2M ups IPO target, but Lombard and Quotient aim lower
This article was originally published in Clinica
Contrary to the trend of medtech companies falling short of their IPO hopes, spinal device specialist K2M has increased the target for its initial public offering. The company said in March that it was hoping to raise $100m – but is now aiming for up to $158m. It said in a filing with the US Securities and Exchange Commission (SEC) that it plans to sell 8.8 million shares at $16-18 each. This total could rise further, with the underwriters having a 30-day option to purchase another 1.3 million shares.